Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
This article was originally published in The Pink Sheet Daily
Executive Summary
Japan's second-biggest pharma offers $3.5 billion to OSI shareholders after 13 months of rejection by the target's management.